Literature DB >> 11836121

Development of a highly selective EP2-receptor agonist. Part 2: identification of 16-hydroxy-17,17-trimethylene 9beta-chloro PGF derivatives.

Kousuke Tani1, Atsushi Naganawa, Akiharu Ishida, Hiromu Egashira, Kenji Sagawa, Hiroyuki Harada, Mikio Ogawa, Takayuki Maruyama, Shuichi Ohuchida, Hisao Nakai, Kigen Kondo, Masaaki Toda.   

Abstract

Further chemical modification of 1a and 2 was undertaken to identify a more chemically stable selective EP2-receptor agonist for development as a clinical candidate. 9beta-chloro PG analogues 4a-e and 5a, c-e were found to be potent and selective EP2-receptor agonists. Among them, the compound 4aLy, which is a chemically stabilized lysine salt of 4a, exhibited an excellent profile both in biological activities and physicochemical properties. The agonist 4aLy was found to suppress uterine motility in anesthetized pregnant rats, while PGE2 stimulated uterine motility. Structure-activity relationships (SARs) are discussed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11836121     DOI: 10.1016/s0968-0896(01)00370-4

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  1 in total

Review 1.  Prostanoid receptor EP2 as a therapeutic target.

Authors:  Thota Ganesh
Journal:  J Med Chem       Date:  2013-12-04       Impact factor: 7.446

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.